<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943679</url>
  </required_header>
  <id_info>
    <org_study_id>B20210618</org_study_id>
    <nct_id>NCT04943679</nct_id>
  </id_info>
  <brief_title>Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC</brief_title>
  <official_title>Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With Pegylated Interferon Alfa-2b in Patients With Advanced-Stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to analyze the safety, tolerability, and efficacy of treatment using&#xD;
      combination of Pegylated Interferon Alfa-2b and anti-PD-1/PD-L1 antibodies for patients with&#xD;
      advanced hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of combination anti-PD-1/PD-L1 antibodies and peginterferon alfa-2b for adult&#xD;
      patients (≥18) with advanced hepatocellular carcinoma. Each 21 day dosing period will&#xD;
      constitute a cycle.&#xD;
&#xD;
      Pegylated Interferon Alfa-2b has been proven to prolong the survival of HCC patients.&#xD;
      Pegylated Interferon Alfa-2b is given subcutaneously, weekly during each 21-day cycle, for at&#xD;
      least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable&#xD;
      toxicity, or consent withdrawal.&#xD;
&#xD;
      Anti-PD-1/PD-L1 antibodies (including pembrolizumeb, nivolumab, sintilimab, toripalimab,&#xD;
      camrelizumeb, tislelizumab and atezolizumab etc.) are given intravenously at assigned dose.&#xD;
      Treatment may continue until disease progression, intolerable toxicity, or consent&#xD;
      withdrawal.&#xD;
&#xD;
      This study is aimed to evaluate the safety and efficacy of the combination of Pegylated&#xD;
      Interferon Alfa-2b and PD-1/PD-L1 mAb in unresectable late-stage HCC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last treatment dose</time_frame>
    <description>Safety will be monitored by addressing and recording all adverse events (AEs), serious adverse events (SAEs) and specific laboratory abnormalities (worst grade). Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS) [ Time Frame: 2 years ]</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To the relief time (TOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of relief(DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-month survival rate</measure>
    <time_frame>9-month</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month survival rate</measure>
    <time_frame>12-month</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b</arm_group_label>
    <description>Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-1/PD-L1</intervention_name>
    <description>Intravenous injection for up to 2 years</description>
    <arm_group_label>Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Interferon Alfa</intervention_name>
    <description>3 µg/kg every week by subcutaneous injection for up to 2 years</description>
    <arm_group_label>Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced HCC patients who received the combination therapy with Anti-PD-1/PD-L1 Antibodies&#xD;
        Plus Pegylated Interferon Alfa-2b Treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years old, male or female&#xD;
&#xD;
          2. Advanced hepatocellular carcinoma (cannot be removed or metastasized) diagnosed&#xD;
             clinically or pathologically, at least one measurable lesion without local treatment,&#xD;
             Child-Pugh A ;Barcelona Clinic Liver Cancer(BCLC) staging is stage B or C&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1&#xD;
&#xD;
          4. Patient has given written informed consent.&#xD;
&#xD;
          5. The function of important organs meets the requirements&#xD;
&#xD;
          6. Expected survival ≥12 weeks&#xD;
&#xD;
          7. Non-surgical sterilization or women of childbearing age need to use a&#xD;
             medically-accepted contraceptive (such as an intrauterine device, contraceptive or&#xD;
             condom) during the study period and within 3 months after the end of the study&#xD;
             treatment period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1.The patient has any active autoimmune disease or a history of autoimmune disease (such as&#xD;
        the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis,&#xD;
        enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid Hyperfunction;&#xD;
        patients with vitiligo; complete remission of asthma in childhood, can be included without&#xD;
        any intervention after adulthood; asthma patients who require bronchodilators for medical&#xD;
        intervention cannot be included); 2.The patient is using immunosuppressive agents or&#xD;
        systemic hormonal therapy to achieve immunosuppressive purposes (agents amount &gt; 10 mg /&#xD;
        day of prednisone or other therapeutic hormones), and continue to use within 2 weeks before&#xD;
        enrollment; 3.Have clinical symptoms or disease that are not well controlled 4.Significant&#xD;
        clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior&#xD;
        to randomization 5.Arterial/venous thrombosis in the first 6 months of randomization&#xD;
        6.According to the investigator, the patient has other factors that may affect the results&#xD;
        of the study or lead to the termination of the study, such as alcohol abuse, drug abuse,&#xD;
        other serious diseases (including mental illness) requiring combined treatment, and serious&#xD;
        laboratory abnormalities.，with family or social factors, it will affect the safety of&#xD;
        patients.&#xD;
&#xD;
        7.Liver tumor burden greater than 50% of the total liver volume, or patients who have&#xD;
        previously undergone liver transplantation;Known for a history of central nervous system&#xD;
        metastasis or hepatic encephalopathy;Severe allergic reactions to other monoclonal&#xD;
        antibodies;&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Xu, M.D.&amp;Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Ma, M.D.</last_name>
    <phone>+86 18721278764</phone>
    <email>191784843@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Ma</last_name>
      <phone>+86 18721278764</phone>
      <email>191784843@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009 Oct 8;361(15):1437-47. doi: 10.1056/NEJMoa0901282.</citation>
    <PMID>19812400</PMID>
  </reference>
  <reference>
    <citation>Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632. [Epub ahead of print]</citation>
    <PMID>30359157</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.</citation>
    <PMID>31790344</PMID>
  </reference>
  <reference>
    <citation>Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.</citation>
    <PMID>33442540</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Anti-PD-1 antibody</keyword>
  <keyword>Interferon Alfa</keyword>
  <keyword>Anti-PD-L1 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

